New drug duo aims to wipe out breast cancer before surgery
NCT ID NCT07294534
First seen Dec 26, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tests whether a new combination of drugs (HLX87 and HLX22) works better than the standard treatment for people with HER2-positive early or locally advanced breast cancer. About 817 participants will receive the drugs before surgery to see if the cancer completely disappears. The goal is to improve the chances of a full response before the main treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.